Catalyst Pharmaceuticals ($CPRX) reported its fourth quarter and full year results. The company incurred a GAAP net loss of $18.07 million or $0.22 per basic and diluted share, compared to a GAAP net loss of $20.23 million or $0.25 per basic and diluted share, for the 2015 fiscal year.  For the fourth quarter of the year, the company’s GAAP net loss stood at $4.16 million or $0.05 per basic and diluted share, compared to a GAAP net loss of $5.81 million, or $0.07 per basic and diluted share, for the 2015 fiscal year. 

The company also met several milestones during the previous year as it completed  enrollment in LEMS (LMS-003) and CMS (CMS-001) clinical trials. The company also recently announced its new collaboration with Biocept ($BIOC). Under this deal, Biocept will provide its Target Selector platform to screen participants in a Phase 3 study assessing Firdapse (amifampridine phosphate) in patients with Eaton Myasthenic Syndrome (LEMS).

Catalyst stock has shown strong performance in this year so far as it jumped over 44 percent during this time period. In the past 12 months it has gained 38 percent. The stock is expected to keep up its robust performance in the near future as the company moves ahead with its ambitious plans.